<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medical  Diagnosis</journal-title></journal-title-group><issn pub-type="epub">2164-540X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/MD.2015.53010</article-id><article-id pub-id-type="publisher-id">MD-16107</article-id><article-categories><subj-group subj-group-type="heading"><subject>MD20150300000_33719008.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  循环microRNAs在乳腺癌诊治中的应用
  The Diagnostic and Therapeutic Application of Circulating microRNAs in Breast Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>薛</surname><given-names>丽</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>白</surname><given-names>玉杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>海南医学院海南省干细胞研究所，海南 海口</addr-line></aff><aff id="aff1"><addr-line>海南医学院科学实验中心，海南 海口</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>xueli-65@163.com(薛丽)</email>;<email>yujiebai@163.com(白玉)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>09</month><year>2015</year></pub-date><volume>05</volume><issue>03</issue><fpage>47</fpage><lpage>53</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  微小核糖核酸(microRNAs, miRNAs)是一类具有调控功能的小分子非编码核糖核酸，与肿瘤的发生有密切关系。大量研究也充分证实了miRNAs在乳腺癌中的作用。循环miRNAs (circulating miRNAs)指存在于血液或其他体液中的细胞外游离microRNAs，具有稳定性好、取材方便、创伤小，可反复取样检测等优点，且与肿瘤发生和发展相关，因此被认为是最具潜力的肿瘤标志之一。本综述主要总结循环miRNAs在乳腺癌早期诊断、预后预测及指导治疗等方面研究及其临床应用进展，并探讨循环miRNAs临床应用所面临的挑战和需解决的问题。
   
  MicroRNAs (miRNAs) are a class of short non-coding regulatory RNAs with an etiological contribution to carcinogensis. The involvement of miRNAs in breast cancer has been reiterated and irrefutably proved by many studies. Circulating miRNAs refer to the cell free miRNAs in the blood or other body fluids, with characteristics such as remarkable stability, ease of access, minimal invasiveness, possibility of repeated sampling, and proven roles in cancer development and progression, so it has been regarded as one of the most potential biomarkers of tumor. This review focuses on recent-finding of circulating miRNAs as biomarkers in early diagnostic, prognostic indications and treatment selection, along with an appraisal of the translational implication of this field. We also addressed the future and the problems and challenges that need to be overcome to achieve clinical implementation of circulating miRNAs.
  
 
</p></abstract><kwd-group><kwd>微小核糖核酸，乳腺癌，生物标志，诊断，治疗, microRNA</kwd><kwd> Breast Cancer</kwd><kwd> Biomarker</kwd><kwd> Diagnosis</kwd><kwd> Therapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>循环microRNAs在乳腺癌诊治中的应用<sup> </sup></title><p>薛丽<sup>1</sup>，白玉杰<sup>2</sup></p><p><sup>1</sup>海南医学院科学实验中心，海南 海口</p><p><sup>2</sup>海南医学院海南省干细胞研究所，海南 海口</p><p>Email: xueli-65@163.com, yujiebai@163.com</p><p>收稿日期：2015年9月6日；录用日期：2015年9月22日；发布日期：2015年9月29日</p><disp-formula id="hanspub.16107-formula216"><graphic xlink:href="http://html.hanspub.org/file/5-2170089x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>微小核糖核酸(microRNAs, miRNAs)是一类具有调控功能的小分子非编码核糖核酸，与肿瘤的发生有密切关系。大量研究也充分证实了miRNAs在乳腺癌中的作用。循环miRNAs (circulating miRNAs)指存在于血液或其他体液中的细胞外游离microRNAs，具有稳定性好、取材方便、创伤小，可反复取样检测等优点，且与肿瘤发生和发展相关，因此被认为是最具潜力的肿瘤标志之一。本综述主要总结循环miRNAs在乳腺癌早期诊断、预后预测及指导治疗等方面研究及其临床应用进展，并探讨循环miRNAs临床应用所面临的挑战和需解决的问题。</p><p>关键词 :微小核糖核酸，乳腺癌，生物标志，诊断，治疗</p><disp-formula id="hanspub.16107-formula217"><graphic xlink:href="http://html.hanspub.org/file/5-2170089x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>近年来我国乳腺癌发病率和死亡率逐年上升，实现乳腺癌早期诊断、疗效监测和预后预测，准确和实用的诊断是前提。目前临床常用的、以肿瘤组织标本为基础的病理和分子诊断，因为取材困难、有创伤或风险性、不能多次获取标本等局限性，无法满足早期诊断和指导个体化治疗的要求，更难以对疗效、术后复发和转移进行动态监测。因此，迫切需要无创伤或创伤小、能反复多次检测的样本替代肿瘤组织。体液(包括外周血、尿液、唾液等)标本具有相对安全、创伤小、可反复取样等优点，目前已有肿瘤相关蛋白如CEA、CA153等方法用于肿瘤辅助诊断，但敏感性和特异性较低。</p><p>微小核糖核酸(microRNA)是小分子非编码RNA，特异性降解靶mRNA或抑制翻译，发挥转录后调控功能。许多研究证实MiRNA参与人体多种生理和病理过程，尤其在肿瘤的发生和发展过程中的作用备受关注。而存在于外周血和体液中的游离miRNAs (循环miRNAs)，因具有出现早、分子小、含量多、稳定性高、组织和肿瘤特异性等优点，是最具潜力的肿瘤分子标志之一。自从2008年被发现以来得到了广泛关注和大量研究，有望应用于乳腺癌的风险预测、早期诊断、分子分型、疗效预测与监测、预后预测等各个阶段。本综述将总结循环miRNAs在乳腺癌诊断和治疗中的最新研究和应用进展、并展望临床应用前景和尚需解决的问题。</p></sec><sec id="s4"><title>2. miRNAs的功能和特性</title><p>在细胞核内miRNA基因由RNA聚合酶(Rnase-II)转录生成初始miRNA (pri-miRNA)，再经Pasha (RNase-II Drosha与DGCR8蛋白组成的复合体)剪切生成70-90核苷酸的miRNA前体(pre-miRNA)，在输出蛋白(exportin5)的辅助下从细胞核转运至细胞浆中。经Dicer(RNAse III)进一步降解生成19-24个核苷酸的成熟miRNA。成熟miRNA与Argonaute蛋白等共同构成RNA诱导的沉默复合体(RNA-induced silencing complex, RISC)，miRNA特异性识别并结合靶mRNA发挥调控作用。miRNA与靶mRNA完全互补时，RICS中Argonaute蛋白发挥切割作用降解mRNA；而当miRNA与靶mRNA不完全互补时，结合于mRNA的3’-UTR的RICS阻滞蛋白的翻译过程。</p><p>目前miRNA数据库收集的人miRNAs达到2578条，所识别的靶mRNA 3’-UTR结合位点超过45,000个，人体2/3的编码基因受到miRNA调控。一种miRNA可调控多个靶mRNAs，同时同一个miRNA也可能受多个miRNA调控，因此构成复杂的调控网络。miRNA基因约50%位于基因间区域(intergenic region)，50%位于内含子区域(intronic region)，内含子区域的miRNAs半数以上与肿瘤相关。miRNA基因多位于染色体的脆性位点区域，而这些区域在肿瘤细胞中常发生扩增或缺失，扩增区域的miRNAs发挥类似癌基因作用，而缺失区域的miRNAs类似肿瘤抑制基因。</p><p>miRNAs不仅调控癌基因、抑癌基因编码蛋白的表达，也调控肿瘤发生发展相关信号途径中蛋白、肿瘤微环境中血管上皮细胞、免疫细胞的重要蛋白。因此miRNA与肿瘤的发生发展、转移和复发密切相关，也可通过调控药物靶分子、药物转运蛋白、甲基化或组蛋白修饰酶、细胞周期调控蛋白，影响药物敏感性和继发耐药等。</p><p>miRNA不仅调控细胞内的转录和翻译，还以微囊(microvesicles)或外泌体(exosome)为载体，通过“细胞间通讯”调控其它细胞。Le等[<xref ref-type="bibr" rid="hanspub.16107-ref1">1</xref>] 发现高转移性乳腺癌细胞分泌含有miR-200的外泌体，被低转移性乳腺癌细胞所内吞后，转化为高转移性乳腺癌细胞。Bovy等[<xref ref-type="bibr" rid="hanspub.16107-ref2">2</xref>] 最新发现乳腺癌肿瘤周围上皮细胞所分泌外泌体中miR-503水平低，化疗后外泌体中的miR-503水平增高，miR-503可调控其靶基因CCND2和CCND3，抑制肿瘤细胞增殖和转移。因此，miRNAs介导肿瘤细胞之间、肿瘤细胞与肿瘤微环境中其他细胞间的相互作用，充当“信使分子”的功能。</p><p>肿瘤患者外周血和体液中的循环miRNAs水平和种类与肿瘤组织中miRNA存在关联，循环miRNA来源于肿瘤细胞坏死裂解或者主动分泌等。循环miRNAs包裹于微囊或外泌体中，或与蛋白(如Argonaute、高密度脂蛋白等)结合，可抵御体液中RNA酶的降解，因此具有高稳定性。在高温、酸碱、反复冻融等条件下保持稳定，在石蜡包埋组织标本中能稳定保存数年，加之取材方便等优点，是比较理想的检测分析材料。</p></sec><sec id="s5"><title>3. 循环microRNAs在乳腺癌中应用</title><p>miRNAs与肿瘤发生、发展和药物反应等密切相关。肿瘤组织原位杂交等实验证明miRNA的表达水平和分布与肿瘤起源、组织分型和分期相关，miRNA可区分肿瘤类型及其分化程度，是最有潜力的肿瘤分子标志之一。依据临床意义可分为诊断标志(diagnostic biomarkers)、预后标志(prognostic biomarkers)和预测标志(predictive biomarkers)。</p><sec id="s5_1"><title>3.1. 乳腺癌诊断生物标志</title><p>尽管赫赛汀等靶向药物，以及生物治疗等新医疗技术提高乳腺癌的疗效和生存率，但早期诊断依然决定预后的最主要因素。早期局部乳腺癌的5年生存率高达99%，临界期患者可达到84%，而晚期和转移癌患者仅为24%。钼靶X线检测是目前临床最常用筛查的方法，但高假阳性(12.1%~65.8%)使患者接受不必要的影像检测或活检。钼靶X线结合CT、核磁共振等可提高早期诊断率，但费用高不适合作为筛查方法。</p><p>肿瘤患者循环miRNAs由坏死肿瘤细胞释放，或者活肿瘤细胞主动分泌，直接来源于肿瘤细胞[<xref ref-type="bibr" rid="hanspub.16107-ref3">3</xref>] ，可能与肿瘤细胞存在一致性。Si等[<xref ref-type="bibr" rid="hanspub.16107-ref4">4</xref>] 比较48例早期乳腺癌组织和100份血清样本中的miRNAs。发现miR-92a表达降低、miR-21表达增高在组织和血清中呈一致性变化，且变化程度与肿瘤大小和淋巴结转移状态相关。可见循环miRNAs具有组织和肿瘤特异性，其含量和组成变化直接反应肿瘤来源和发生，甚至在肿瘤发生的早期出现，具备肿瘤诊断生物标志的潜力。</p><p>Roth等[<xref ref-type="bibr" rid="hanspub.16107-ref5">5</xref>] 对59例原发乳腺癌患者、30例转移性乳腺癌患者和29例健康对照者的血清miRNAs比较分析，发现miR-155、miR-10b和miR-34a水平不仅可区分乳腺癌与健康对照，而且可鉴别原发和转移性乳腺癌。Schwarzenbach等[<xref ref-type="bibr" rid="hanspub.16107-ref6">6</xref>] 研究102例手术前和34例手术后乳腺癌患者、32例良性肿瘤患者和53例健康人血浆miRNAs水平，发现miR-20a和miR-21在良、恶性肿瘤患者均高于健康对照，而乳腺癌患者血浆miR-214显著高于良性肿瘤患者。循环miRNAs对早期乳腺癌检测敏感性和特异性优于目前临床常用的肿瘤标志物检测，例如Gao等[<xref ref-type="bibr" rid="hanspub.16107-ref7">7</xref>] 对89例早期乳腺癌患者和55例健康对照者，分别采用qRT-PCR测定循环miR-21，用化学发光法检测CEA和CA-153，循环miR-21检测敏感性为87.6%，特异性为87.3%；而CEA和CA-153的敏感性分别为22.4%和15.7%。Liu等[<xref ref-type="bibr" rid="hanspub.16107-ref8">8</xref>] 对包括16篇文献报道，31项研究，1668例乳腺癌和1111例健康对照的荟萃分析(meta-analysis)显示miRNAs对乳腺癌诊断的总敏感性为77%、特异性为88%，阳性似然率(PLR)为4.2%、阴性似然率(NLR) 0.29、曲线下面积(AUC)为0.89。</p><p>新一代测序和PCR芯片等高通量技术分析循环miRNAs表达谱，可提高检测的灵敏度。Kodahl等[<xref ref-type="bibr" rid="hanspub.16107-ref9">9</xref>] 采用miRNA芯片分析了48例ER<sup>+</sup>乳腺癌患者和24例健康对照者血清miRNAs表达谱，筛选得到9种miRNAs (miR-15a、miR-18a、miR-107、miR-133a、miR-139-5p、miR-143、miR-145、miR-365、miR-425)。对60例早期乳腺癌患者和51例健康对照者血清样本进行验证，9个miRNAs表达谱综合运算得出的风险值准确性远高于单一miRNA，不仅可以诊断早期乳腺癌，还可以用于乳腺癌发病风险的筛查。Cuk等[<xref ref-type="bibr" rid="hanspub.16107-ref10">10</xref>] 类似的研究也筛选出一组miRNAs (miR-127-3p、miR-376a、miR-652、miR-148b、miR-409-3p、miR-801、miR-376c)可鉴别乳腺癌和良性肿瘤(AUC = 0.81)，且对年轻女性(&lt;50岁)的准确性更高(AUC = 0.86)。</p></sec><sec id="s5_2"><title>3.2. 乳腺癌预后生物标志</title><p>乳腺癌转移和术后复发是影响预后和生存期的重要难题，目前临床采用的CT、PET/CT、MRI等影像技术难以早期发现转移癌。miRNAs调控肿瘤细胞游走、侵袭、上皮间质细胞转换、新生血管相关蛋白，与肿瘤的恶性程度和转移复发密切相关，近年来研究发现与肿瘤细胞及肿瘤微环境组成细胞相关miRNAs，如上皮细胞相关miRNAs (miR-10b、miR-31、miR-141、miR-200b、miR-205、miR-335)、肿瘤相关成纤维细胞相关miRNAs (miR-21、miR-26b)和新生血管相关miRNA (miR-126)，这些循环miRNAs表达水平和变化可作为乳腺癌复发和转移的生物标志。</p><p>Madhavan等[<xref ref-type="bibr" rid="hanspub.16107-ref11">11</xref>] 采用miRNA芯片筛选与循环肿瘤细胞(CTC)状态相关的mRNAs，在61例阳性(CTC<sup>+</sup>)、60例低水平和72例阴性(CTC<sup>−</sup>)转移性乳腺癌(MBC)患者中验证，发现血浆miRNAs (miR-141、miR-200a、miR-200b、miR-200c、miR-203、miR-210、miR-375、miR-801)在CTC<sup>+</sup>的MBC患者血浆中水平高于CTC<sup>−</sup>的MBC患者，其中miR-200b表达差异最为显著。单独miR-200b和上述miRNAs表达谱均与总生存期(OS)和无进展生存期(PFS)相关，表达谱的预后预测准确性优于单一miR-200b。Kleivi Sahlberg等[<xref ref-type="bibr" rid="hanspub.16107-ref12">12</xref>] 对60例ER<sup>−</sup>/PR<sup>−</sup>/HER2<sup>−</sup> (TNBC)乳腺癌患者血清miRNAs表达谱分析，筛选并验证一组miRNAs (miR-18b、miR-103、miR-107、miR-652)表达水平与肿瘤复发和总生存期相关。Madhavan等[<xref ref-type="bibr" rid="hanspub.16107-ref11">11</xref>] 发现在CTC阳性的乳腺癌患者中循环miR-141、miR-200a、miR-200b、miR-203和miR-210表达水平升高，miR-375和miR-768-3p表达水平降低，循环miRNA表达谱与患者总生存期的相关性高于CTC状态。Eichelser等[<xref ref-type="bibr" rid="hanspub.16107-ref13">13</xref>] 也报道了血浆中外泌体的miRNA-373表达水平在TNBC和ER<sup>−</sup>/PR<sup>−</sup>乳腺癌患者高于激素受体阳性(ER<sup>+</sup>/PR<sup>+</sup>)乳腺癌患者，miR-373水平与侵袭表型相关。类似研究也相继发现血浆/血清miR-210、miR-21、miR-155、miR-214、miR-19a等表达水平与淋巴结转移或远处转移相关[<xref ref-type="bibr" rid="hanspub.16107-ref14">14</xref>] -[<xref ref-type="bibr" rid="hanspub.16107-ref16">16</xref>] 。</p><p>因此循环miRNAs可作为一种低创伤的预后评价和转移复发监测手段，准确性甚至高于CTC状态分析。</p></sec><sec id="s5_3"><title>3.3. 乳腺癌疗效监测生物标志</title><p>miRNAs调控激素受体、药物代谢、细胞周期、凋亡、组蛋白修饰和DNA损伤修复等相关蛋白的表达[<xref ref-type="bibr" rid="hanspub.16107-ref17">17</xref>] ，与乳腺癌治疗疗效关系密切。同时因循环miRNAs可以重复取材和连续动态监测等优点，使得循环miRNAs成为理想的预测生物标志，可指导个体化用药并动态监测治疗效果和发现获得性耐药等。</p><p>Heneghan等[<xref ref-type="bibr" rid="hanspub.16107-ref18">18</xref>] 对乳腺癌和对照组血液中7种候选miRNAs比较分析，确认miR-195和let-7a在乳腺癌患者高表达，手术切除肿瘤后分别降低11倍和19倍，miR-195和let-7a不仅可诊断乳腺癌，还可作为治疗效果评价指标。Li等[<xref ref-type="bibr" rid="hanspub.16107-ref19">19</xref>] 比较分析多柔比星+紫杉醇联合化疗敏感和耐药的乳腺癌患者的血清miRNAs，发现miR-19a和miR-205在药物敏感和耐药组间相差显著，预测耐药的敏感性达81.25%，特异性为75%。Jung等[<xref ref-type="bibr" rid="hanspub.16107-ref20">20</xref>] 报道HER2<sup>+</sup>乳腺癌患者治疗前血浆miR-210表达水平低，采用曲妥珠单抗或手术治疗后血浆miR-210水平升高，且与临床病理完全缓解水平相一致。更多临床研究也相继发现血miR-21、miR-125b、miR-373、miR-210、miR-30c、miR-519、miR-221等与他莫昔芬、曲妥珠单抗、拉帕替尼药物敏感性相关[<xref ref-type="bibr" rid="hanspub.16107-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.16107-ref22">22</xref>] 。Mackenzie等报道miR-10b、miR-21、miR-155表达水平高的TNBC患者，预后较差，总生存期和无复发生存期均较短。相比目前采用的以mRNA为基础的预后预测(如FDA批准的Oncotype DX和Mannaprint芯片)，循环miRNA具有稳定和便捷的优势。</p></sec></sec><sec id="s6"><title>4. 应用前景及尚待解决问题</title><p>循环miRNAs具备作为肿瘤生物标志的特征和临床应用潜力，但目前仍处于临床前研究阶段，在成功应用于临床之前尚有一些理论和技术问题有待解决：从已发表文献不难看出，虽然大量临床和基础研究筛选到与乳腺癌诊断、病理分期、受体状态、药物反应、复发转移等相关的miRNAs，但结果的可重复性和一致性不高，甚至有些相互矛盾。例如Ng等报道原发乳腺癌患者血浆miR-145表达水平降低，而Mar-Aguilar等却报道miR-145表达水平增高。其原因既有肿瘤异质性和miRNAs本身特性也有研究方法(如患者选择、分析样本、检测方法、数据处理和实验设计等)的差别：1) 乳腺癌与其他肿瘤一样存在高度异质性，发生和发展过程涉及多个基因的改变，相关的miRNAs数量和种类众多。循环miRNAs既可由坏死肿瘤细胞被动释放，又可由活细胞主动分泌，因而循环miRNAs的组成和含量可能呈现随机性和动态波动性；2) 许多相关性研究采用病例–对照方法，研究对象的特征(年龄、种族、病理分期、肿瘤组织学分型，分子亚型)影响研究结果。例如不同种族患者的miRNAs表达谱可存在差异，Zhao等[<xref ref-type="bibr" rid="hanspub.16107-ref23">23</xref>] 对比白人和黑人乳腺癌患者全血miRNAs表达谱，绝大多数不一致，仅见miR-181a和miR-1304在2个人群呈一致性； 3) 检测分析样本的影响：循环miRNAs的研究采用了全血、血浆和血清样本，全血标本因受到淋巴细胞内miRNAs的干扰，对结果的影响较大；血清和血浆相对更为稳定，但也存在细微差别，因在凝血过程中少量淋巴细胞裂解释放miRNAs，通常血清中miRNAs浓度略高于血浆；4) 样本量的大小、取样时机、筛选和验证程序等实验设计的影响：一些研究的样本量偏小造成结果的偏差；循环miRNAs受到手术、药物治疗等影响，选择手术后或治疗后患者会影响用于早期诊断分子标志的miRNAs的筛选结果；5) 检测和数据处理方法：qRT-PCR是最常用检测方法之一，PCR结果的校正方法和参照不同也会产生偏差。如Cookson等对血清miRNAs的RT-PCR结果用miR-16等内参基因校正，未发现显著差异的miRNAs，而改用miRNA的平均值进行校正后获得阳性结果。</p><p>目前新一代测序技术(NGS)应用于miRNAs研究，将加快miRNAs的筛查和发现。陆续出现的新技术也将拓展样本范围和简化检测操作，如Erbes等[<xref ref-type="bibr" rid="hanspub.16107-ref24">24</xref>] 从尿液中筛选4种miRNA (miR-155、miR-21、miR-125b、miR-451)在乳腺癌患者高于健康对照，尿液miRNA检测无创伤也更加方便。Asaga等[<xref ref-type="bibr" rid="hanspub.16107-ref25">25</xref>] 建立了不需要分离RNA直接RT-PCR检测miRNAs的技术，操作更为简便和快捷。</p><p>随着循环miRNAs临床研究和方法的成熟，可以预期不久的将来可应用于临床肿瘤的早期诊断、用药指导和预后预测等，服务于乳腺癌的个性化诊断和治疗。而且，miRNAs在无典型症状或临床诊断乳腺癌前数年可被检出，有望用于高风险人群的早期筛查和预防。</p></sec><sec id="s7"><title>文章引用</title><p>薛丽,白玉杰. 循环microRNAs在乳腺癌诊治中的应用The Diagnostic and Therapeutic Application of Circulating microRNAs in Breast Cancer[J]. 医学诊断, 2015, 05(03): 47-53. http://dx.doi.org/10.12677/MD.2015.53010</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.16107-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Le, M.T., Hamar, P., Guo, C.Y., Basar, E., Perdigão-Henriques, R., Balaj, L. and Lieberman, J. (2014) miR-200- containing extracellular vesicles promote breast cancer cellmetastasis. The Journal of Clinical Investigation, 124, 5109-5128. &lt;br&gt;http://dx.doi.org/10.1172/JCI75695</mixed-citation></ref><ref id="hanspub.16107-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bovy, N., Blomme, B., Frères, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J.A., Noël, A., Thiry, M., Jérusalem, G., Josse, C., Bours, V., Tabruyn, S.P. and Struman, I. (2015) Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget, 6, 10253-10266.</mixed-citation></ref><ref id="hanspub.16107-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Cookson, V.J., Bentley, M.A., Hogan, B.V., Horgan, K., Hayward, B.E., Hazelwood, L.D. and Hughes, T.A. (2012) Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cellular Oncology, 35, 301-308. &lt;br&gt;http://dx.doi.org/10.1007/s13402-012-0089-1</mixed-citation></ref><ref id="hanspub.16107-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Si, H.Y., Sun, X.M., Chen, Y.J., Cao, Y., Chen, S.M., Wang, H.C. and Hu, C.J. (2013) Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. Journal of Cancer Research and Clinical Oncology, 139, 223-229. &lt;br&gt;http://dx.doi.org/10.1007/s00432-012-1315-y</mixed-citation></ref><ref id="hanspub.16107-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Roth, C., Rack, B., Müller, V., Janni, W., Pantel, K. and Schwarzenbach, H. (2010) Circulating microRNAs as blood- based markers for patients with primary and metastatic breast cancer. Breast Cancer Research, 12, R90.  
&lt;br&gt;http://dx.doi.org/10.1186/bcr2766</mixed-citation></ref><ref id="hanspub.16107-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Schwarzenbach, H, Milde-Langosch, K., Steinbach, B., Müller, V. and Pantel, K. (2012) Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Research and Treatment, 134, 933-941.  
&lt;br&gt;http://dx.doi.org/10.1007/s10549-012-1988-6</mixed-citation></ref><ref id="hanspub.16107-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gao, J., Zhang, Q., Xu, J., Guo, L. and Li, X. (2013) Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chinese Journal of Cancer Research, 25, 743-748.</mixed-citation></ref><ref id="hanspub.16107-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L.H., Wang, S., Cao, X.T. and Liu, J.C. (2014) Analysis of circulating microRNA biomarkers for breast cancer detection: A meta-analysis. Tumor Biology, 35, 12245-12253. &lt;br&gt;http://dx.doi.org/10.1007/s13277-014-2533-5</mixed-citation></ref><ref id="hanspub.16107-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kodahl, A.R., Lyng, M.B., Binder, H., Cold, S., Gravgaard, K., Knoop, A.S. and Ditzel, H.J. (2014) Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. Molecular Oncology, 8, 874-883. &lt;br&gt;http://dx.doi.org/10.1016/j.molonc.2014.03.002</mixed-citation></ref><ref id="hanspub.16107-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Cuk, K., Zucknick, M., Heil, J., Madhavan, D., Schott, S., Turchinovich, A., et al. (2013) Circulating microRNAs in plasma as early detection markers for breast cancer. International Journal of Cancer, 32, 1602-1612.  
&lt;br&gt;http://dx.doi.org/10.1002/ijc.27799</mixed-citation></ref><ref id="hanspub.16107-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Madhavan, D., Zucknick, M., Wallwiener, M., Cuk, K., Modugno, C., Scharpff, M., Schott, S., Heil, J., Turchinovich, A., Yang, R.X., Benner, A., Riethdorf, S., Trumpp, A., Sohn, C., Pantel, K., Schneeweiss, A. and Burwinkel, B. (2012) Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clinical Cancer Research, 18, 5972-5982. &lt;br&gt;http://dx.doi.org/10.1158/1078-0432.CCR-12-1407</mixed-citation></ref><ref id="hanspub.16107-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kleivi Sahlberg, K., Bottai, G., Naume, B., Burwinkel, B., Calin, G.A., Børresen-Dale, A.L. and Santarpia, L. (2015) A serum microRNA signature predicts tumor relapse and survival in triple-negativebreast cancer patients. Clinical Cancer Research, 21, 1207-1214.</mixed-citation></ref><ref id="hanspub.16107-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Eichelser, C., Stückrath, I., Müller, V., Milde-Langosch, K., Wikman, H., Pantel, K. and Schwarzenbach, H. (2014) Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget, 5, 9650-9663.</mixed-citation></ref><ref id="hanspub.16107-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Jung, E.J., Santarpia, L., Kim, J., Esteva, F.J., Moretti, E., Buzdar, A.U., Di Leo, A., Le, X.F., Bast Jr., R.C., Park, S.T., Pusztai, L. and Calin, G.A. (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 118, 2603-2614. &lt;br&gt;http://dx.doi.org/10.1002/cncr.26565</mixed-citation></ref><ref id="hanspub.16107-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Sun, Y., Wang, M.G., Lin, G.J., Sun, S.P., Li, X.X., Qi, J. and Li, J.M. (2012) Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS ONE, 7, e47003. &lt;br&gt;http://dx.doi.org/10.1371/journal.pone.0047003</mixed-citation></ref><ref id="hanspub.16107-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Anfossi, S., Giordano, A., Gao, H., Cohen, E.N., Tin, S., Wu, Q., et al. (2014) High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS ONE, 9, e83113. &lt;br&gt;http://dx.doi.org/10.1371/journal.pone.0083113</mixed-citation></ref><ref id="hanspub.16107-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Eroles, P., Tormo, E., Pineda, B., Espin, E. and Lluch, A. (2015) MicroRNAs in breast cancer: one more turn in regulation. Current Drug Targets, (Epub Ahead of Print).</mixed-citation></ref><ref id="hanspub.16107-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Heneghan, H.M., Miller, N., Lowery, A.J., Sweeney, K.J., Newell, J. and Kerin, M.J. (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Annals of Surgery, 251, 499-505.</mixed-citation></ref><ref id="hanspub.16107-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Li, Q., Liu, M., Ma, F., Luo, Y., Cai, R.G., Wang, L.M., Xu, N.Z. and Xu, B.H. (2014) Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal Asubtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS ONE, 9, e104870.</mixed-citation></ref><ref id="hanspub.16107-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Jung, E.J., Santarpia, L., Kim, J., Esteva, F.J., Moretti, E., Buzdar, A.U., et al. (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 118, 2603-2614.  
&lt;br&gt;http://dx.doi.org/10.1002/cncr.26565</mixed-citation></ref><ref id="hanspub.16107-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Müller, V., Gade, S., Steinbach, B., Loibl, S., von Minckwitz, G., Untch, M., Schwedler, K., Lübbe, K., Schem, C., Fasching, P.A., Mau, C., Pantel, K. and Schwarzenbach, H. (2014) Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: A translational research project within the Geparquinto trial. Breast Cancer Research and Treatment, 147, 61-68.  
&lt;br&gt;http://dx.doi.org/10.1007/s10549-014-3079-3</mixed-citation></ref><ref id="hanspub.16107-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ward, A., Shukla, K., Balwierz, A., Soons, Z., König, R., Sahin, O., et al. (2014) MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. The Journal of Pathology, 233, 368-379. &lt;br&gt;http://dx.doi.org/10.1002/path.4363</mixed-citation></ref><ref id="hanspub.16107-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, H., Shen, J., Medico, L., Wang, D., Ambrosone, C.B. and Liu, S. (2010) A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE, 5, e13735</mixed-citation></ref><ref id="hanspub.16107-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Erbes, T., Hirschfeld, M., Rücker, G., Jaeger, M., Boas, J., Iborra, S., Mayer, S., Gitsch, G. and Stickeler, E. (2015) Feasibility of urinary microRNA detection in breast cancer patients and itspotential as an innovative non-invasive biomarker. BMC Cancer, 15, 193. &lt;br&gt;http://dx.doi.org/10.1186/s12885-015-1190-4</mixed-citation></ref><ref id="hanspub.16107-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Asaga, S. and Hoon, D.S. (2013) Direct serum assay for microRNA in cancer patients. Methods in Molecular Biology, 1024, 147-155. &lt;br&gt;http://dx.doi.org/10.1007/978-1-62703-453-1_11</mixed-citation></ref></ref-list></back></article>